Clearside Biomedical (NASDAQ:CLSD) Releases Earnings Results

Clearside Biomedical (NASDAQ:CLSD) issued its quarterly earnings data on Friday. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.47), Zacks reports.

Clearside Biomedical Price Performance

CLSD traded up $0.13 during trading on Friday, hitting $3.82. The company had a trading volume of 43,879 shares, compared to its average volume of 104,350. Clearside Biomedical has a 1-year low of $3.32 and a 1-year high of $17.10. The company has a market cap of $20.01 million, a PE ratio of -0.69 and a beta of 2.04. The business has a 50-day moving average of $4.09 and a 200-day moving average of $7.99.

Analyst Ratings Changes

CLSD has been the topic of several analyst reports. Needham & Company LLC downgraded Clearside Biomedical from a “moderate buy” rating to a “hold” rating and set a $45.00 target price on the stock. in a report on Thursday, July 17th. Chardan Capital lowered shares of Clearside Biomedical from a “buy” rating to a “neutral” rating in a research note on Friday, July 18th. Stifel Nicolaus cut shares of Clearside Biomedical from a “buy” rating to a “hold” rating and set a $30.00 target price on the stock. in a research report on Friday, July 18th. HC Wainwright downgraded shares of Clearside Biomedical from a “buy” rating to a “neutral” rating and set a $75.00 target price for the company. in a research note on Friday, July 18th. Finally, Weiss Ratings started coverage on shares of Clearside Biomedical in a report on Saturday, November 1st. They set a “sell (e+)” rating for the company. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $63.00.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.